Hyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"
Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). Clinical safety confirmed through COVID-19 and Dengue clinical trials. Class-wide efficacy proven by accumulated research data for...
Hyundai Bioscience: "Able to Supply Antiviral Drug in Event of Ebola or Hantavirus Spread"
SEOUL, South Korea, May 20, 2026 /PRNewswire/ -- Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks...
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the...